Modulation of mucosal immunity against Campylobacter jejuni by orally administered cytokines.
The effect of oral recombinant interleukin (rIL) treatment on the course of Campylobacter jejuni infection and the development of mucosal immunity in mice was investigated. rIL-2, rIL-5, and rIL-6 were administered to mice at 24 and 6 h before infection and at 0, 24, and 48 h after infection with C. jejuni HC, and the subsequent development of an immune response and intestinal colonization resistance were determined. In this model, orally administered cytokines retained their biological activities with no apparent side effects. Following infection, initial bacterial counts in fecal samples collected from cytokine-treated and untreated mice were similar. However, within 48 h of infection a greater than 3-log-unit reduction in the number of C. jejuni shed in the feces was found for rIL-6-treated animals. Colonization levels were similarly reduced in rIL-5-treated mice, although the rate of clearance was somewhat slower. In contrast, rIL-2 treatment had no significant effect on colonization levels compared with that in controls. Oral rIL-6 treatment was also associated with enhanced intestinal and systemic Campylobacter-specific immunoglobulin A responses compared with those observed in either rIL-5- or rIL-2-treated animals. Upon rechallenge, initial colonization in all cytokine-treated groups was approximately 2 log units lower than that in controls. However, local infection was controlled only in rIL-2-treated mice over time. rIL-5 and rIL-6 treatment had only a marginal effect on colonization resistance following rechallenge. On the basis of these results, it appears that rIL-5 or rIL-6 may function to modulate the induction and/or expression of anti-C. jejuni immunity through different mechanisms.
Baqar
S
S
Division of Enteric Diseases, Naval Medical Research Institute, Bethesda, Maryland 20889-5607.
Pacheco
N D
ND
Rollwagen
F M
FM
D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D000284:Administration, Oral; D000818:Animals; D000917:Antibody Formation / Q000187:drug effects / Q000276:immunology; D002169:Campylobacter Infections / Q000188:drug therapy* / Q000276:immunology*; D016123:Campylobacter jejuni; D004305:Dose-Response Relationship, Drug; D005260:Female; D007378:Interleukins / Q000494:pharmacology*; D007413:Intestinal Mucosa / Q000187:drug effects* / Q000276:immunology*; D051379:Mice; D008807:Mice, Inbred BALB C; D008954:Models, Biological; D011994:Recombinant Proteins / Q000494:pharmacology
D000276:Adjuvants, Immunologic; D007378:Interleukins; D011994:Recombinant Proteins